Form 8-K

8-K — IGC Pharma, Inc.

Accession: 0001185185-26-002922

Filed: 2026-07-14

Period: 2026-07-13

CIK: 0001326205

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — igc8k071326.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (igcex99-1.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

GRAPHIC (ex99-1_003.jpg)

GRAPHIC (ex99-1_004.jpg)

GRAPHIC (ex99-1_005.jpg)

GRAPHIC (ex99-1_006.jpg)

GRAPHIC (ex99-1_007.jpg)

GRAPHIC (ex99-1_008.jpg)

GRAPHIC (ex99-1_009.jpg)

GRAPHIC (ex99-1_010.jpg)

GRAPHIC (ex99-1_011.jpg)

GRAPHIC (ex99-1_012.jpg)

GRAPHIC (ex99-1_013.jpg)

GRAPHIC (ex99-1_014.jpg)

GRAPHIC (ex99-1_015.jpg)

GRAPHIC (ex99-1_016.jpg)

GRAPHIC (ex99-1_017.jpg)

GRAPHIC (ex99-1_018.jpg)

GRAPHIC (ex99-1_019.jpg)

GRAPHIC (ex99-1_020.jpg)

GRAPHIC (ex99-1_021.jpg)

GRAPHIC (ex99-1_022.jpg)

GRAPHIC (ex99-1_023.jpg)

GRAPHIC (ex99-1_024.jpg)

GRAPHIC (ex99-1_025.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: igc8k071326.htm · Sequence: 1

false

0001326205

2026-07-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): July 13, 2026

IGC

PHARMA, INC.

(Exact

name of registrant as specified in charter)

Maryland

001-32830

20-2760393

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S.

Employer Identification No.)

10224

Falls Road, Potomac, Maryland 20854

(Address

of principal executive offices) (Zip Code)

(301)

983-0998

(Registrant’s

telephone number, including area code)

Not applicable

(Former

Name or Former Address, if Changed since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.0001 par value

IGC

NYSE

American

Indicate by check mark whether the Registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐.

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On July 13, 2026, IGC Pharma, Inc. (“IGC” or the “Company”)

furnished an updated investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is furnished

as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation,

in whole or in part and with modifications or supplements from time to time, in meetings and communications with investors, analysts,

potential strategic partners and others, and at conferences and other business events.

The information contained in the Investor Presentation is summary information

and should be considered in the context of the Company’s filings with the Securities and Exchange Commission and its other public

disclosures. The Investor Presentation speaks only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation

to update or revise the Investor Presentation except as required by applicable law.

The information furnished pursuant to this Item 7.01, including Exhibit

99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

By furnishing the information contained in the Investor Presentation, the Company makes no admission as to the materiality of any information

therein that is required to be disclosed solely by reason of Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

IGC Pharma Investor Presentation, dated July 2026.

104

Cover Page Interactive Data File, formatted in Inline XBRL

Forward-Looking Statements:

This Current Report on Form 8-K and the Investor Presentation furnished

as Exhibit 99.1 contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements

are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially,

including risks related to the Company’s ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes,

demonstrate safety and efficacy, obtain regulatory approvals, successfully develop and commercialize its product candidates, and achieve

market acceptance, as well as other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission,

including its most recent Annual Report on Form 10-KT and subsequent reports filed with the SEC.

Forward-looking statements include, without limitation, statements regarding

the anticipated timing, enrollment, conduct and results of the CALMA Phase 2 trial of IGC-AD1; the potential safety or efficacy of IGC-AD1;

interim, blinded or preliminary clinical observations and the extent to which they may or may not be predictive of final results; comparisons

to other products, product candidates or companies; the potential size of any addressable market; and the possibility that favorable Phase

2 results or other clinical, regulatory or business developments could result in an increase or inflection in the Company’s valuation.

Any valuation metrics, valuation ranges, comparable-company analyses or

potential valuation-inflection scenarios contained in the Investor Presentation are illustrative and hypothetical, are based on assumptions

and circumstances that may not occur, and do not constitute an appraisal or estimate of the fair or intrinsic value of the Company or

its securities, a projection or forecast of future financial performance, a price target, investment advice or a recommendation to purchase

or sell any security. Comparable companies may differ materially from the Company in their stage of development, clinical results, product

profiles, financial resources, market opportunities and other respects. There can be no assurance that the CALMA trial will produce favorable

results or that, even if favorable results are obtained, the Company’s stock price or market capitalization will increase or achieve

any valuation referenced or implied in the Investor Presentation.

Interim and blinded clinical data are preliminary, are not statistically

powered to demonstrate efficacy, may change as additional data become available, and are not necessarily predictive of topline or final

results. IGC-AD1 is an investigational product candidate and has not been approved by the U.S. Food and Drug Administration or any other

regulatory authority. Cross-trial comparisons are not based on head-to-head clinical trials and are inherently limited.

Forward-looking statements speak only as of the date on which they are

made. The Company undertakes no obligation to update or revise any forward-looking statement except as required by applicable law.

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto

duly authorized.

IGC Pharma, Inc.

Dated: July 13, 2026

By:

/s/ Ram Mukunda

Name:

Ram Mukunda

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: igcex99-1.htm · Sequence: 2

Exhibit 99.1

Advancing Alzheimer’s Care. Improving Lives. NYSE American: IGC

SAFE HARBOR : Forward - Looking Statements and Important Cautionary Information: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements include statements regarding the timing, conduct and results of the CALMA Phase 2 trial; the safety and efficacy of IGC - AD1; regulatory and commercialization plans; market opportunities; and the possibility that favor able clinical results or other developments could result in an increase or inflection in IGC Pharma’s valuation. Forward - looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the possibility of delays in enrollment, database l ock or data readout; unfavorable or inconclusive clinical results; safety findings; regulatory delays or denials; financing requirements; competition; and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. Forward - looking statements speak only as of the date of this presentation, and the Company undertakes no obligation to update them ex cep t as required by law. Any valuation metrics, comparable - company analyses, valuation ranges or potential valuation - inflection scenarios presented are illustrative and hypothetical. They are based on assumptions and circumstances that may not occur and do not constitute a projection, forecast, appraisal, estimate of fair or intrinsic value, price target, investment recommendation or gu arantee of future stock price, market capitalization or financial performance. Comparable companies may differ materially from IGC Ph arm a, and there can be no assurance that favorable Phase 2 results, if obtained, would result in any increase in the Company’s stoc k p rice or valuation. Blinded pooled analyses combine participants assigned to IGC - AD1 and placebo and do not permit assessment of treatment effect or efficacy. Observed changes may reflect treatment effect, placebo response, regression to the mean, backgr oun d care, trial participation, attrition or other factors. Such data are preliminary, may change following database cleaning and unb linding, and may not predict topline or final results. IGC - AD1 is investigational and has not been approved by the FDA or any other regul atory authority. Cross - trial comparisons are not head - to - head comparisons and are inherently limited. IGC Pharma, Inc. · NYSE American: IGC

OVERVIEW OF IGC IGC Pharma, Inc. · NYSE American: IGC

INVESTMENT OPPORTUNITY IN ALZHEIMER’S DISEASE (AD) Illustrative Potential Valuation Scenarios → ~$30M ~$300 – $500M ~$2 – $4B 7/2026 Current market cap Near - term Potential inflection based on positive Phase 2 results Long - term Potential inflection if disease - modifying catalysts succeed Valuation scenarios are illustrative and hypothetical, not projections, forecasts, price targets, or guarantees.

THE PROBLEM One in three Americans over 85 has Alzheimer’sKM1

AGITATION IN ALZHEIMER’S 76% of patients experience agitation or other neuropsychiatric symptoms 139M people projected to live with dementia by 2050 - Alzheimer’s is the leading cause Agitation is defined as physical or verbal aggression, restlessness, pacing, among others. Agitation drives earlier institutionalization, higher mortality, and devastating caregiver burden. IGC Pharma, Inc. · NYSE American: IGCKM1

OUR SOLUTION IGC Pharma is Developing a Major TherapyKM1

IGC - AD1 Therapeutic Targets Patent - protected Oral liquid — practical for elderly Alzheimer’s patients and caregivers Multiple neurobiological pathways targeted by IGC - AD1 Neuroinflammation CB1 receptor signaling Neurotransmitter regulation IGC - AD1 INVESTIGATIONAL IGC Pharma, Inc. · NYSE American: IGC

IGC - AD1 IGC Pharma, Inc. · NYSE American: IGC

PHASE 1: NPS MEASURED BY NPI - 12 IGC - AD1 showed improvement in Neuropsychiatric Symptoms (NPS) in Phase 1 Trial Across qd , bid, & tid dosing, IGC - AD1 led to an overall improvement in NPS as measured by the NPI - 12 KEY DOMAINS SHOWING IMPROVEMENT: Agitation Anxiety Depression Caregiver Distress Total NPI - 12 Baseline Day 15 Total Average NPI Score 31.5 14.8 ** Cohort 1 % Change 53.02% p value: 0.005 22.2 12.4 * Cohort 2 % Change 44.14% p value: 0.024 16.0 7.9 * Cohort 3 % Change 50.63% p value: 0.021 IGC Pharma, Inc. · NYSE American: IGC

PHASE 2 - CALMA TRIAL STATUS The multicenter CALMA trial of IGC - AD1 for agitation in Alzheimer’s dementia. 146 Target number of participants >80% of participants have completed dosing Previously reported interim analysis showed a reduction in agitation at 2 weeks NEAR - TERM CATALYSTS Completion of enrollment + topline readout IGC Pharma, Inc. · NYSE American: IGC 6 – 10 weeks for the current standard of care, Brexpiprazole, based on published data. vs KM1

UNITED STATES & CANADA ADDITIONAL SITES • Dent Neurosciences Research Center • BayCare Health System • ClinCloud • Global Medical Institutes Florida • Neurostudies • Tandem Intermediate • Tekton Research • Integrative Clinical Trials • Ichor Research • Lynn Health Science Institute • Senior Adults Specialty Research • Dominion Medical Associates • University of Puerto Rico • SCB Research Center SITES CONDUCTING CALMA IGC Pharma, Inc. · NYSE American: IGC

CALMA PHASE 2 · PROGRESS REPORT BLINDED POOLED DATA Blinded pooled data include both IGC - AD1 and placebo participants and cannot establish treatment effect or efficacy; observed changes may not predict unblinded results 0 - 5 - 10 - 15 Baseline Week 2 Week 6 Visit LS Mean Change from Baseline (CMAI) −13.6 −14.9 WEEK 2 −13.6 LS mean change in CMAI from baseline (n=107) WEEK 6 −14.9 LS mean change in CMAI from baseline BLINDED POOLED INVESTIGATIONAL IGC Pharma, Inc. · NYSE American: IGC n=(104)KM1

CALMA INTERIM RESULTS (N=26): IGC - AD1 COMPARED TO BREXPIPRAZOLE DATA Brexpiprazole is the current standard of care to treat agitation in AD In interim analysis, IGC - AD1 showed numerically earlier and larger changes than those reported in selected published Brexpiprazole studies. IGC AD - 1: Potentially faster acting, larger effect size, and excellent safety profile * CMAI Least Squared mean change from baseline at EOT comparing active and placebo groups A) IGC - AD1 1ml BID trial (NCT05543681) and Brexpiprazole trial 0.5 to 2 mg flexible doses trial (NCT01922258). * p<0.05, ** p<0.01, b p<0.001; Mixed Model of Repeated Measures. SE: S ta ndard Error; CMAI: Cohen - Mansfield Agitation Inventory. • This is a not a direct comparison Grossberg GT, Kohegyi E, Mergel V, et al. Am J Geriatr Psychiatry. 2020;28(4):383 - 400. doi:10.1016/j.jagp.2019.09.009 IGC Pharma, Inc. · NYSE American: IGCKM1

INTERIM DATA (n=26) - POTENTIAL FOR REDUCING SLEEP DISTURBANCE Clinical reduction in sleep & nighttime disturbance at week 2 sustained through End of Trial (EOT) - 1 - 2 - 3 - 4 - 5 1 2 EOT WEEK Placebo IGC - AD1 Active Placebo WEEK 2 Sleep Disturbance Reduced 71% (p=0.012) WEEK 6 (EOT) Sleep Disturbance Reduced 78% (p=0.02) (1) NPI - 12 Sleep Subdomain Least Squared Mean change from baseline comparing placebo and active groups in the interim data IGC Pharma, Inc. · NYSE American: IGCKM1

APPROVED DRUGS (COMPETITION) AXS - 05 (Dextromethorphan and bupropion) A combination therapy approved in April 2026. IGC Pharma, Inc. · NYSE American: IGC Rexulti (Brexpiprazole) Atypical antipsychotic approved in May 2023 BLACK BOX WARNING

IGC HAS SEVERAL PLATFORMS WITH IP Foreign Patents Granted US Patents Granted Pending Patent Applications Description Lead Drug Candidate - 2 1 ● Composition & Method for treating CNS Disorders IGC - AD1 1 1 9 ● Composition & Method for treating CNS Disorders IGC - AD1 - - 6 ● Naphthalene Monoimide Derivatives with ability to impact A β protein build - up. TGR - 63 - - 5 ● Naphthalene Monoimide Derivatives with ability to impact Tau aggregation and neurofibrillary tangle formation IGC - 1C - - 4 ● Naphthalene Monoimide Derivatives with ability to impact A β plaque build - up and neurofibrillary tangle formation IGC - M3 1 1 0 ● Naphthalene diimide Derivatives with ability to self - assemble molecular interactions for biological and nonbiological systems including some cancers IGC - 514 - - 1 ● Composition, Synthesis & Medical use of Hybrid Molecule IGC - LMP - 2 - ● Composition & Method for treating Seizures in humans & Cats/Dogs Epilepsy - 1 - ● Natural formulation with Cyproheptadine for treating Cachexia & Eating Disorders Eating Disorders - 1 - ● Formulation for Treating Stuttering & Symptoms of Tourette Syndrome Stuttering & Tourette Syndrome 2 2 - ● Formulation containing Cobalamin and method for pain management Pain - - 1 ● Multi agent system for end - to - end heterogenous data set harmonization IGC - AHA - - 1 ● Explainable multimodal transformer - based system for neurodegenerative diseases clinical support MINT - AD - - 1 ● Methods and compositions for treating sleep disturbance and sleep – wake cycle disruption in alzheimer’s disease Sleep 4 10 29 We have 29 active patent applications which are distributed among the US, Canada, Europe, Colombia, India, Brazil, Japan and Hong Kong and 14 granted patents in US, Canada, Europe and Mexico. In - house patents / applications Patents / applications acquired through exclusive license agreements

POTENTIAL CATALYSTS Laura Sanchez , Quality Control Manager & Dr. Jagadeesh Rao, Principal Scientist at IGC Pharma Headquarters in Potomac, MarylandKM1KM2

MARKET: BLOCKBUSTER OPPORTUNITY North America & Europe market sizing for agitation in AD EST. ANNUAL REVENUE $3B 3% adoption $5B 5% adoption $10B 10% adoption ASSUMPTIONS 15M* Individuals with AD 11M Agitation in AD (76%) $750 Monthly price * Sources: Alzheimer’s Association, Alzheimer Europe, Harvard School of Public Health, Alzheimer’s Disease International IGC Pharma, Inc. · NYSE American: IGC

VALUATION INFLECTION EXAMPLES ~$30M $350 – $750M IGC today Potential Post Phase 2 valuation COMPANY PHASE 2 POST Positive PHASE 2 PEAK DIFFERENCE Annovis (ANVS) AD/PD $200M (2021) → $700M (2021) ~$500M Axsome (AXSM) AD $50M (2019) → $800M (2019) ~$750M Anavex AD/CNS $150M (2016) → $500M (2018) ~$350M IGC Pharma, Inc. · NYSE American: IGC Valuation scenarios are illustrative and positive phase 2 results, if obtained, may not result in any increase in IGC’s stock pr ice or market capitalization.

POTENTIAL VALUATION INFLECTION Investors today are positioned before principal value - inflection events ~ $30m Current valuation July 10 2026 $350m – $750m 4 - 9 months 2026 - 2027 Positive phase 2 results $2B – $4B ~36 - 48 months 2029+ Positive phase 2 results in a disease - modifying therapy IGC Pharma, Inc. · NYSE American: IGC Valuation scenarios are illustrative and positive phase 2 results, if obtained, may not result in any increase in IGC’s stock price or market capitalization.

EXECUTIVE MANAGEMENT & BOARD EXECUTIVE MANAGEMENT Ram Mukunda Biomedical Engineer CEO Claudia Grimaldi Psychologist, MBA, Vice President INDEPENDENT BOARD Richard Prins Chairman James Moran Former Congressman Terry Lierman Human Virology (IHV) CORPORATE ADVISORY BOARD Terry McAuliffe Former Governor of Virginia Howard Gutman Ambassador to Belgium ( rtd .) IGC Pharma, Inc. · NYSE American: IGC

TEAM IGC Pharma, Inc. · NYSE American: IGC Dr. Juan Manuel Orjuela, MD Neuropsychiatrist Dr. Diego Rodriguez, Ph.D. Medicinal Chemist Evelyn Gutiérrez, Eng. MPH Sr. Manager - CALMA Paola Ruiz, MS Sr. Manager AI Systems Maria Tangarife, MS Neuroscientist Margarita Venegas, MS Clinical Psychologist Dr. Varduhi Ghazaryan, MD - MPH - Medical Director Dr. Jagadeesh Rao, Ph.D. Doctorate in Neuroscience Principal Scientist Dr. Sudip Sinha, Ph.D. Doctorate in Naturopathy CALMA - Operations

BOARD OF ADVISORS IGC Pharma, Inc. · NYSE American: IGC Prof. Elliot Hong, MD Professor Psychiatrist Prof. Chuanhai Cao, PhD Professor of Pharmaceutical Science s Prof. Jeffrey Cummings , MD, ScD, Chair of the ACTC Neuropsychiatric Symptoms Committee Prof. Pablo Arbelaez, PhD Professor Biomedical Engineering Prof. Joseph Fortunak , PhD Professor Chemistry and Pharmaceutical Science s Dr. Munish Mehra , PhD Statistics PHARMACEUTICAL SCIENCES, PSYCHIATRY, NEUROLOGY, STATISTICS, AND AI

CONTACT Ram Mukunda ram@igcpharma.com Claudia Grimaldi cgrimaldi@igcpharma.com www.igcpharma.com THANK YOU Advancing Alzheimer’s Care . Improving Lives . NYSE American: IGC

GRAPHIC

Filename: image_001.jpg · Sequence: 3

Binary file (1858 bytes)

Download image_001.jpg

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (429488 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 5

Binary file (747062 bytes)

Download ex99-1_002.jpg

GRAPHIC

Filename: ex99-1_003.jpg · Sequence: 6

Binary file (154244 bytes)

Download ex99-1_003.jpg

GRAPHIC

Filename: ex99-1_004.jpg · Sequence: 7

Binary file (251396 bytes)

Download ex99-1_004.jpg

GRAPHIC

Filename: ex99-1_005.jpg · Sequence: 8

Binary file (535158 bytes)

Download ex99-1_005.jpg

GRAPHIC

Filename: ex99-1_006.jpg · Sequence: 9

Binary file (405252 bytes)

Download ex99-1_006.jpg

GRAPHIC

Filename: ex99-1_007.jpg · Sequence: 10

Binary file (380851 bytes)

Download ex99-1_007.jpg

GRAPHIC

Filename: ex99-1_008.jpg · Sequence: 11

Binary file (246735 bytes)

Download ex99-1_008.jpg

GRAPHIC

Filename: ex99-1_009.jpg · Sequence: 12

Binary file (326566 bytes)

Download ex99-1_009.jpg

GRAPHIC

Filename: ex99-1_010.jpg · Sequence: 13

Binary file (283445 bytes)

Download ex99-1_010.jpg

GRAPHIC

Filename: ex99-1_011.jpg · Sequence: 14

Binary file (301458 bytes)

Download ex99-1_011.jpg

GRAPHIC

Filename: ex99-1_012.jpg · Sequence: 15

Binary file (354262 bytes)

Download ex99-1_012.jpg

GRAPHIC

Filename: ex99-1_013.jpg · Sequence: 16

Binary file (282260 bytes)

Download ex99-1_013.jpg

GRAPHIC

Filename: ex99-1_014.jpg · Sequence: 17

Binary file (356496 bytes)

Download ex99-1_014.jpg

GRAPHIC

Filename: ex99-1_015.jpg · Sequence: 18

Binary file (321483 bytes)

Download ex99-1_015.jpg

GRAPHIC

Filename: ex99-1_016.jpg · Sequence: 19

Binary file (219036 bytes)

Download ex99-1_016.jpg

GRAPHIC

Filename: ex99-1_017.jpg · Sequence: 20

Binary file (514599 bytes)

Download ex99-1_017.jpg

GRAPHIC

Filename: ex99-1_018.jpg · Sequence: 21

Binary file (476010 bytes)

Download ex99-1_018.jpg

GRAPHIC

Filename: ex99-1_019.jpg · Sequence: 22

Binary file (230946 bytes)

Download ex99-1_019.jpg

GRAPHIC

Filename: ex99-1_020.jpg · Sequence: 23

Binary file (272863 bytes)

Download ex99-1_020.jpg

GRAPHIC

Filename: ex99-1_021.jpg · Sequence: 24

Binary file (241861 bytes)

Download ex99-1_021.jpg

GRAPHIC

Filename: ex99-1_022.jpg · Sequence: 25

Binary file (375179 bytes)

Download ex99-1_022.jpg

GRAPHIC

Filename: ex99-1_023.jpg · Sequence: 26

Binary file (421238 bytes)

Download ex99-1_023.jpg

GRAPHIC

Filename: ex99-1_024.jpg · Sequence: 27

Binary file (389684 bytes)

Download ex99-1_024.jpg

GRAPHIC

Filename: ex99-1_025.jpg · Sequence: 28

Binary file (499563 bytes)

Download ex99-1_025.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 33

v3.26.1

Cover

Jul. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 13, 2026

Entity File Number

001-32830

Entity Registrant Name

IGC

PHARMA, INC.

Entity Central Index Key

0001326205

Entity Tax Identification Number

20-2760393

Entity Incorporation, State or Country Code

Entity Address, Address Line One

10224

Falls Road

Entity Address, City or Town

Potomac

Entity Address, State or Province

Entity Address, Postal Zip Code

20854

City Area Code

(301)

Local Phone Number

983-0998

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value

Trading Symbol

IGC

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration